menu
    • menu
    [{"orgOrder":0,"company":"Arrivent","sponsor":"Arrivent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Firmonertinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase III","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrivent \/ ArriVent","highestDevelopmentStatusID":"10","companyTruncated":"Arrivent \/ ArriVent"},{"orgOrder":0,"company":"Arrivent","sponsor":"Allist Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Furmonertinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arrivent \/ Allist Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Arrivent \/ Allist Pharmaceuticals"},{"orgOrder":0,"company":"Arrivent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Furmonertinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arrivent \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arrivent \/ Undisclosed"},{"orgOrder":0,"company":"Arrivent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Furmonertinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arrivent \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arrivent \/ Undisclosed"},{"orgOrder":0,"company":"Arrivent","sponsor":"Hillhouse Capital Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series A Financing","leadProduct":"Furmonertinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Arrivent","amount2":0.14999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Tablet","sponsorNew":"Arrivent \/ Hillhouse Capital Group","highestDevelopmentStatusID":"15","companyTruncated":"Arrivent \/ Hillhouse Capital Group"},{"orgOrder":0,"company":"Arrivent","sponsor":"Sofinnova Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series B Financing","leadProduct":"Furmonertinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Arrivent","amount2":0.16,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"Tablet","sponsorNew":"Arrivent \/ Sofinnova Investments","highestDevelopmentStatusID":"15","companyTruncated":"Arrivent \/ Sofinnova Investments"},{"orgOrder":0,"company":"Arrivent","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Furmonertinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Arrivent","amount2":0.17999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Arrivent \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Arrivent \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Arrivent","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Furmonertinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Arrivent","amount2":0.14000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Arrivent \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Arrivent \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Arrivent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Furmonertinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arrivent \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arrivent \/ Undisclosed"},{"orgOrder":0,"company":"Arrivent","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Furmonertinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Arrivent","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Arrivent \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Arrivent \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Arrivent","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Furmonertinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Arrivent","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Arrivent \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Arrivent \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Arrivent","sponsor":"InnoCare Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Furmonertinib","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arrivent \/ Arrivent","highestDevelopmentStatusID":"6","companyTruncated":"Arrivent \/ Arrivent"},{"orgOrder":0,"company":"Arrivent","sponsor":"Lepu Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"MRG007","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Arrivent","amount2":1.21,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1.21,"dosageForm":"Undisclosed","sponsorNew":"Arrivent \/ Arrivent","highestDevelopmentStatusID":"4","companyTruncated":"Arrivent \/ Arrivent"},{"orgOrder":0,"company":"Arrivent","sponsor":"Alphamab Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Arrivent","amount2":0.62,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.62,"dosageForm":"Undisclosed","sponsorNew":"Arrivent \/ Arrivent","highestDevelopmentStatusID":"2","companyTruncated":"Arrivent \/ Arrivent"},{"orgOrder":0,"company":"Arrivent","sponsor":"Aarvik Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Arrivent","amount2":0.10000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Arrivent \/ Arrivent","highestDevelopmentStatusID":"4","companyTruncated":"Arrivent \/ Arrivent"},{"orgOrder":0,"company":"Arrivent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Firmonertinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase III","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arrivent \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arrivent \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Arrivent

    Menu

    Arrivent

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Arrivent

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Arrivent

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Firmonertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor a...

                            Details : Firmonertinib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 22, 2025

                            Lead Product(s) : Firmonertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Arrivent

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Arrivent

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Goldman Sachs & Co

                            Deal Size : $75.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            ArriVent Announces Pricing of $75 Million Public Offering

                            Details : ArriVent intends to use the net proceeds to support its activities for AST2818 (firmonertinib), an oral, brain penetrant, EGFR mutation selective inhibitor, for on-small-cell lung cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 01, 2025

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Goldman Sachs & Co

                            Deal Size : $75.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Arrivent

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Arrivent

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Goldman Sachs & Co

                            Deal Size : $75.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            ArriVent Announces Proposed $75 Million Public Offering

                            Details : ArriVent intends to use the net proceeds to support its activities for AST2818 (firmonertinib), an oral, brain penetrant, EGFR mutation selective inhibitor, for on-small-cell lung cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 01, 2025

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Goldman Sachs & Co

                            Deal Size : $75.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Arrivent

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Arrivent

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Firmonertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Allist Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Firmonertinib vs Placebo in Stage IB-IIIB NSCLC w/Uncommon EGFR Post-Surgery

                            Details : Firmonertinib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 08, 2025

                            Lead Product(s) : Firmonertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Allist Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Arrivent

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Arrivent

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MRG007

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Lepu Biopharma

                            Deal Size : $1,207.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ArriVent, Lepu Sign Exclusive License for MRG007 in GI Cancer Treatment

                            Details : Under the terms of the agreement, Lepu Biopharma has granted ArriVent exclusive global rights to develop, manufacture and commercialize MRG007 outside of Greater China.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : $47.0 million

                            January 21, 2025

                            Lead Product(s) : MRG007

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Lepu Biopharma

                            Deal Size : $1,207.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Arrivent

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Arrivent

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : Aarvik Therapeutics

                            Deal Size : $100.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma

                            Details : ArriVent will be responsible for clinical development and commercialization of a novel ADC molecule, for oncology indications, that relies on the unique modular platform developed by Aarvik.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 15, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : Aarvik Therapeutics

                            Deal Size : $100.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Arrivent

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Arrivent

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Alphamab Oncology

                            Deal Size : $615.5 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

                            Details : Through the collaboration, both companies will leverage Alphamab’s proprietary linker-payload platform and glycan-conjugation technology to identify novel ADCs for oncology indications.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 05, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Alphamab Oncology

                            Deal Size : $615.5 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Arrivent

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Arrivent

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Goldman Sachs & Co

                            Deal Size : $175.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            ArriVent Announces Pricing of Upsized Initial Public Offering

                            Details : Proceeds will support NDA approval for furmonertinib, a novel oral EGFR kinase inhibitor with broad activity across EGFR mutations.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 25, 2024

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Goldman Sachs & Co

                            Deal Size : $175.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Arrivent

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Arrivent

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Goldman Sachs & Co

                            Deal Size : $135.7 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Arrivent Unveils $135M IPO Pricing to get Furmonertinib to FDA

                            Details : The net proceeds will be used for the clinical development of (furmonertinib), which focuses on EGFR mutant-selective tyrosine kinase inhibitors that are developed for NSCLC patients.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 22, 2024

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Goldman Sachs & Co

                            Deal Size : $135.7 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Arrivent

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Arrivent

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ArriVent Receives FDA Breakthrough Therapy Designation for Furmonertinib for First-Line Treatment of Advanced ...

                            Details : AST2818 (furmonertinib) is an oral, small molecule, highly brain-penetrant, pan-EGFR mutant inhibitor that targets both classical (exon 19 deletion and L858R) and atypical EGFR mutations, including exon 20 insertion mutations as well as HER2 exon 20 inse...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 30, 2023

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth